About this Research Topic
In the exploration of immunological functions, cancer and autoimmune diseases share a common foundation — the disruption of immune tolerance. Immune tolerance is critical as it enables the body to avoid attacking its own tissues while simultaneously preventing cancer cells from being detected and destroyed by the immune system. This intersection of cancer camouflage and autoimmune attack forms a pivotal area of study, particularly in terms of how immune adaptations in one field can inform treatment strategies in the other.
The investigation of immune checkpoints has dramatically deepened our understanding of these diseases. By exploring such mechanisms, researchers have developed therapies that manipulate immune responses — for instance, checkpoint inhibitors like PD-1 blocking antibodies used in cancer treatment have been mirrored by PD-1 agonists in managing autoimmune conditions. This Research Topic aims to explore novel interventions that can precisely tune the immune response without widespread systemic effects, thereby enhancing patient outcomes in both cancer and autoimmune diseases.
We welcome submissions that deal with the following themes:
o Autoimmune and inflammatory diseases management such as RA, AIH, MS, and RE.
o Strategies for targeting cancer stem cells and examining hematopoietic dynamics.
o Advanced bioinformatics approaches for immune system-related data.
o Combined modalities in cancer treatment utilizing immunotherapy alongside traditional cancer treatments.
o Interactions within the tumor microenvironment and their consequences on therapy outcomes.
o Investigations of immunotherapy-induced reproductive issues in female cancer patients and relationships between autoimmunity, cancer risks, and prognoses.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
The investigation of immune checkpoints has dramatically deepened our understanding of these diseases. By exploring such mechanisms, researchers have developed therapies that manipulate immune responses — for instance, checkpoint inhibitors like PD-1 blocking antibodies used in cancer treatment have been mirrored by PD-1 agonists in managing autoimmune conditions. This Research Topic aims to explore novel interventions that can precisely tune the immune response without widespread systemic effects, thereby enhancing patient outcomes in both cancer and autoimmune diseases.
We welcome submissions that deal with the following themes:
o Autoimmune and inflammatory diseases management such as RA, AIH, MS, and RE.
o Strategies for targeting cancer stem cells and examining hematopoietic dynamics.
o Advanced bioinformatics approaches for immune system-related data.
o Combined modalities in cancer treatment utilizing immunotherapy alongside traditional cancer treatments.
o Interactions within the tumor microenvironment and their consequences on therapy outcomes.
o Investigations of immunotherapy-induced reproductive issues in female cancer patients and relationships between autoimmunity, cancer risks, and prognoses.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Autoimmune disease, rheumatoid arthritis, autoimmune hepatitis, cancer, stem cell, immunotherapy, combination therapy, artificial intelligence, tumor microenvironment, traditional Chinese medicine, immunotherapy related adverse event, immune checkpoint
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
